Serum FSTL3 partially mediated the association of increased FIB-4 fibrosis risk with AMI in NAFLD and T2DM patients without adjusting for other factors, and explained 21.92% of the association (Fig. 4C). This evidence concerns the gene FSTL3 and metabolic dysfunction-associated steatotic liver disease.